Drugs

Drugs Journal

Publication venue for

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022) 2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection 2022
Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy in COVID-19" 2020
Management of Thrombotic Complications in COVID-19: An Update 2020
Pharmaco-Immunomodulatory Therapy in COVID-19. 80:1267-1292. 2020

International Standard Serial Number (ISSN)

0012-6667